---
$id: https://graph.org.ai/products/commodity/51131701
$type: Product
source: UNSPSC
code: "51131701"
title: "Abciximab"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Abciximab

**UNSPSC Code**: 51131701
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody with the molecular formula C2101H3229N551O673S15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X85G7936GV, more generally known as abciximab. European Medicines Agency schedules abciximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00233MIG. The term ABCIXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 13 no. 1, 1999, list 41. ABCIXIMAB is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abciximab under HS 30021091 and SITC 54163. As of Q4 2014, ABCIXIMAB remains the US FDA Preferred Term for this commodity. Abciximab bears US NLM identifiers UMLS ID C0288672 and NCI Concept Code C76128. SMILES: NONE.

